Quantitative analysis of (-)-N-11C-propyl-norapomorphine in vivo binding in nonhuman primates

Journal of Nuclear Medicine

Volumn 45, Issue 2, 2004, Pages 338-346

  Hwang, Dah Ren ^a,b   Narendran, Rajesh ^a,b   Huang, Yiyun ^a,b   Slifstein, Mark ^a,b   Talbot, Peter S ^a,b   Sudo, Yasuhiko ^a,b   Van Berckel, Bart N ^a,b   Kegeles, Lawrence S ^a,b   Martinez, Diana ^a,b   Laruelle, Marc ^a,b  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

11C NPA; D2 agonist; Dopamine; Nonhuman primate; PET

Indexed keywords

N PROPYL NORAPOMORPHINE C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; APOMORPHINE; CARBON; DIAGNOSTIC AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE; N-N-PROPYLNORAPOMORPHINE; PROPYLNORAPOMORPHINE; TRACER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BABOON; BRAIN REGION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; IN VIVO STUDY; ISOTOPE LABELING; NONHUMAN; PLASMA CLEARANCE; POSITRON EMISSION TOMOGRAPHY; PRIMATE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; ANIMAL; BINDING SITE; BRAIN; COMPUTER ASSISTED EMISSION TOMOGRAPHY; MALE; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PAPIO; SCINTISCANNING; TIME;

ANIMALS; APOMORPHINE; BINDING SITES; BRAIN; CARBON RADIOISOTOPES; DOPAMINE AGONISTS; MAGNETIC RESONANCE IMAGING; MALE; PAPIO; RADIOACTIVE TRACERS; RECEPTORS, DOPAMINE D2; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 1542399582     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Seeman P, Van Tol HH. Dopamine receptor pharmacology. Trends Pharmacol Sci. 1994;15:264-270.
2. Vallone D, Picetti R, Borrelli E. Structure and function of dopamine receptors. Neurosci Biobehav Rev. 2000;24:125-132.
3. 2 dopamine receptor. J Biol Chem. 1982;257:6351-6361.
4. Seeman P, Grigoriadis D. Dopamine receptors in brain and periphery. Neurochem Int. 1987;10:1-25.
5. 2 receptors in the rat central nervous system. Neuroscience. 1989;30:767-777.
6. Zahniser NR, Molinoff PB. Effect of guanine nucleotides on striatal dopamine receptors. Nature. 1978;275:453-455.
7. George SR, Watanabe M, Di Paolo T, Falardeau P, Labrie F, Seeman P. The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form. Endocrinology. 1985;117:690-697.
8. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab. 2000;20:423-451.
9. Hwang DR, Kegeles LS, Laruelle M. (-)-N-[(11)C]propyl-norapomorphine: a positron-labeled dopamine agonist for PET imaging of D(2) receptors. Nucl Med Biol. 2000;27:533-539.
10. Cumming P, Wong DF, Dannals RF, et al. The competition between endogenous dopamine and radioligands for specific binding to dopamine receptors. Ann N Y Acad Sci. 2002;965:440-450.
11. Brix G, Zaers J, Adam LE, et al. Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J Nucl Med. 1997;38:1614-1623.
12. 11C]NNC 756. Synapse. 1999;32:93-109.
13. Rowland M, Tozer TN. Clinical Pharmacokinetics. 2nd ed. Philadelphia, PA: Lea & Febiger; 1989:25.
14. Abi-Dargham A, Laruelle M, Seibyl J, et al. SPECT measurement of benzodiazepine receptors in human brain with [123-I]iomazenil: kinetic and equilibrium paradigms. J Nucl Med. 1994;35:228-238.
15. Gandelman MS, Baldwin RM, Zoghbi SS, Zea-Ponce Y, Innis RB. Evaluation of ultrafiltration for the free fraction determination of single photon emission computerized tomography (SPECT) radiotracers: β-CIT, IBF, and iomazenil. J Pharmaceutical Sci. 1994;83:1014-1019.
16. Woods RP, Mazziotta JC, Cherry SR. MRI-PET registration with automated algorithm. J Comput Assist Tomogr. 1993;17:536-546.
17. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol. 1984;15:217-227.
18. 2 receptors in healthy subjects. J Nucl Med. 1994;35:743-754.
19. 123I]iomazenil binding to benzodiazepine receptors in nonhuman primates. I. Kinetic modeling of single bolus experiments. J Cereb Blood Flow Metab.1994;14:439-452.
20. 11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740-747.
21. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153-158.
22. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834-840.
23. 11C]AFM. J Cereb Blood Flow Metab. 2002;22:1377-1398.
24. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;AC19:716-723.
25. Landlaw EM, Distefano JJ III. Multiexponential, multicompartmental, and noncompartmental modeling. II. Data analysis and statistical considerations. Am J Physiol. 1984;246:R665-R677.
26. Carson RE, Parameters estimation in positron emission tomography. In: Schelbert HR, ed. Positron Emission Tomography: Principles and Applications for the Brain and the Heart. New York, NY: Raven Press; 1986:347-390.
27. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage. 1997;6:279-287.
28. 18F]FP-TZTP: control and competition studies. J Cereb Blood Flow Metab. 1998;18:1130-1142.
29. 11C]MDL 100,907. J Cereb Blood Flow Metab. 2000;20:899-909.
30. 11C]flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography. J Cereb Blood Flow Metab. 1991;11:735-744.
31. 11C]-DASB binding to the human serotonin transporter: modeling strategies. J Cereb Blood Flow Metab. 2001;21:1342-1353.
32. 2 receptor binding sites for agonists: a tetrahedral model. Mol Pharmacol. 1985;28:391-399.
33. George SR, Watanabe M, Seeman P. Dopamine D2 receptors in the anterior pituitary: a single population without reciprocal antagonist/agonist states. J Neurochem. 1985;44:1168-1177.
34. Lahti RA, Mutin A, Cochrane EV, et al. Affinities and intrinsic activities of dopamine receptor agonists for the hD21 and hD4.4 receptors. Eur J Pharmacol. 1996;301:R11-R13.
35. 2 (long) dopamine receptors: ligand binding and functional assays. Br J Pharmacol. 1998;124:978-984.
36. Slifstein M, Laruelle M. Effects of statistical noise on graphic analysis of PET neuroreceptor studies. J Nucl Med. 2000;41:2083-2088.
37. 11C]WAY- 100635 binding parameters with reference tissue models: effect of violations of model assumptions. Nucl Med Biol. 2000;27:487-492.
38. Carson RE, Breier A, Debartolomeis A, et al. Quantification of amphetamine-induced changes in [C-11]raclopride binding with continuous infusion. J Cereb Blood Flow Metab. 1997;17:437-447.
39. 2 receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab. 2001;21:1034-1057.
40. 123I]iomazenil binding to benzodiazepine receptors in nonhuman primates. II. Equilibrium analysis of constant infusion experiments and correlation with in vitro parameters. J Cereb Blood Flow Metab. 1994;14:453-465.